首页> 外文期刊>The Lancet >COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
【24h】

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

机译:Covid-19化疗或其他抗癌治疗癌症患者的死亡率:一项潜在的队列研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with cancer.
机译:背景下具有癌症的个体,特别是那些正在接受系统性抗癌治疗的人,已经假定到Covid-19的死亡风险增加。 该猜想对患有癌症和数据的患者的治疗具有相当大的影响,多期面研究支持这种假设是因为大流行的突发事件稀缺。 我们旨在描述癌症患者的临床和人口统计学特征和Covid-19结果。

著录项

  • 来源
    《The Lancet》 |2020年第10241期|共8页
  • 作者单位

    Univ Birmingham Inst Canc &

    Genom Sci Birmingham B15 2TT W Midlands England;

    Univ Birmingham Ctr Computat Biol Birmingham W Midlands England;

    Univ Birmingham Inst Canc &

    Genom Sci Birmingham B15 2TT W Midlands England;

    Univ Oxford Nuffield Dept Med Oxford England;

    Univ Oxford Dept Oncol Oxford England;

    Univ Birmingham Inst Immunol &

    Immunotherapy Birmingham W Midlands England;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医药、卫生;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号